Institut für Pharmakologie und präventive Medizin (IPPMed GmbH)
Industry / private company
Location:
Cloppenburg / Mahlow / München,
Germany (DE)
ISNI: 0000000483890378
ROR: https://ror.org/00j0wh784
Dynamics of Hemoglobin A1c, Body Mass Index, and Rates of Severe Hypoglycemia in 4434 Adults with Type 1 or Type 2 Diabetes After Initiation of Continuous Glucose Monitoring (2022)
Lanzinger S, Best F, Bergmann T, Laimer M, Lipovsky B, Danne T, Zimny S, et al.
Journal article
DYNAMICS OF CHOLESTEROL AND BLOOD PRESSURE IN 4,484 ADULTS WITH TYPE 1 OR TYPE 2 DIABETES AFTER INITIATION OF CGM (2022)
Lanzinger S, Best F, Bergmann T, Laimer M, Lipovsky B, Danne T, Zimny S, et al.
Conference contribution
Impact of pre-existing comorbidities on outcomes of patients undergoing surgical aortic valve replacement – rationale and design of the international IMPACT registry (2021)
Bakhtiary F, Ahmad AES, Autschbach R, Benedikt P, Bonaros N, Borger M, Dewald O, et al.
Journal article
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine (2021)
Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, et al.
Journal article
Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin (2021)
Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel AM, Bosch A, Ott C, et al.
Conference contribution
Effects of the sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure (2021)
Kolwelter J, Bosch A, Jung S, Stabel L, Kannenkeril D, Ott C, Bramlage P, et al.
Journal article
Changes in HbA(1c), BMI and rates of severe hypoglycaemia in 4,113 adults with type 1 or type 2 diabetes using continuous glucose monitoring systems (2021)
Lanzinger S, Best F, Bergmann T, Laimer M, Lipovsky B, Danne T, Zimny S, et al.
Conference contribution
Reduction of inappropriate implantable cardioverter-defibrillator therapies using enhanced supraventricular tachycardia discriminators: the ReduceIT study. (2021)
Geller JC, Woehrle A, Busch M, Elsaesser A, Kleemann T, Birkenhauer F, Bramlage P, Veltmann C
Journal article
EFFECTS OF THE SGLT2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION IN PATIENTS WITH CHRONIC HEART FAILURE (2021)
Kolwelter J, Bosch A, Jung S, Linz P, Kannenkeril D, Nagel AM, Ott C, et al.
Conference contribution
Management of patients with severe aortic stenosis in the TAVI-era: How recent recommendations are translated into clinical practice (2021)
Lauten A, Rudolph TK, Messika-Zeitoun D, Thambyrajah J, Serra A, Schulz E, Frey N, et al.
Journal article